Pfizer vs Qualcomm: Revenue, Profit and Business Model
Pfizer reported $62.6B of revenue in FY2025 and $7.8B of net income. Qualcomm reported $44.3B of revenue in FY2025 and $5.5B of net income.
Latest financial snapshot
Financial summary
Pfizer
Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%.
Qualcomm
Qualcomm's revenue has swung with the smartphone cycle: $44.2B in FY2022, $35.8B in FY2023, $39.0B in FY2024 and a record $44.284B in FY2025. FY2025 operating income was $12.355B, but GAAP net income dropped to $5.541B because of a large non-cash income tax charge booked in the September 2025 quarter. FY2026 has been tougher on the top line. Q2 revenue was $10.599B, and Q3 revenue fell 4% year over year to $9.9B with GAAP EPS of $1.87 and non-GAAP EPS of $2.21, as higher memory costs squeezed handset demand. QTL revenue was $1.3B in Q3. Qualcomm returned $2.3B to shareholders that quarter and guided Q4 FY2026 revenue to $9.7B-$10.5B.
Revenue and profit by year
Pfizer
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | 12.4% | -1.6% | Source |
| FY2024 | $63.6B | $8B | 12.6% | +6.8% | Source |
| FY2023 | $59.6B | $2.1B | 3.6% | -41.1% | Source |
| FY2022 | $101.2B | $31.4B | 31.0% | +24.5% | Source |
| FY2021 | $81.3B | $22B | 27.0% | +95.2% | Source |
| FY2020 | $41.7B | $9.2B | 22.0% | +1.8% | Source |
| FY2019 | $40.9B | $16B | 39.2% | +0.2% | Source |
| FY2018 | $40.8B | $11.2B | 27.3% | -22.3% | Source |
| FY2017 | $52.5B | $21.3B | 40.6% | -0.5% | Source |
| FY2016 | $52.8B | $7.2B | 13.7% | — | Source |
Qualcomm
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $44.3B | $5.5B | 12.5% | +13.7% | Source |
| FY2024 | $39B | $10.1B | 26.0% | +8.8% | Source |
| FY2023 | $35.8B | $7.2B | 20.2% | -19.0% | Source |
| FY2022 | $44.2B | $12.9B | 29.3% | +31.7% | Source |
| FY2021 | $33.6B | $9B | 26.9% | +42.6% | Source |
| FY2020 | $23.5B | $5.2B | 22.1% | -3.1% | Source |
| FY2019 | $24.3B | $4.4B | 18.1% | +7.4% | Source |
| FY2018 | $22.6B | -$5B | -22.0% | +1.6% | Source |
| FY2017 | $22.3B | $2.4B | 11.0% | -5.5% | Source |
| FY2016 | $23.6B | $5.7B | 24.2% | — | Source |
Where the revenue comes from
Pfizer
- Patented medicines
Core revenue
Prescription drugs protected by exclusivity and clinical differentiation.
- Vaccines
Major revenue contributor
Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.
- Oncology
Strategic growth driver
Cancer medicines, antibody-drug conjugates, and Seagen-related assets.
- Hospital and anti-infective products
Meaningful contributor
Sterile injectables, anti-infectives, and hospital therapies.
- Collaborations and alliances
Supplemental
Co-promoted products and partnered scientific platforms.
Qualcomm
- QCT Handsets~63%
Snapdragon processors, modems and RF chips for smartphones: $27.793B in FY2025. Handset revenue fell 20% to $5.1B in Q3 FY2026 as memory costs hurt phone demand.
- QCT IoT~15%
Chips for industrial devices, networking, XR headsets, PCs and consumer electronics: $6.617B in FY2025 and $1.8B in Q3 FY2026.
- QCT Automotive~9%
Snapdragon Digital Chassis cockpit, ADAS and connectivity platforms: $3.957B in FY2025, up from $2.9B in FY2024, and $1.6B in Q3 FY2026 (up 61%).
- QTL Licensing and other~13%
Royalties on Qualcomm's cellular patents plus smaller strategic initiatives. QTL revenue was $1.3B in Q3 FY2026 at a 69% EBT margin, making it a disproportionate profit contributor.
Business model and strategy
Pfizer
How it makes money
Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Revenue is concentrated in large franchises such as Eliquis (co-commercialized with Bristol Myers Squibb), the Prevnar pneumococcal vaccines, the Vyndaqel tafamidis family, Ibrance, Xtandi and the Seagen antibody-drug conjugates.
Growth strategy
Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).
Competitive advantage
Pfizer's advantage is scale in late-stage development, regulatory filings, manufacturing and commercialization. The BioNTech partnership showed it: BioNTech supplied the mRNA science, while Pfizer ran the global Phase 3 trial with more than 40,000 participants, built ultra-cold distribution and manufactured billions of Comirnaty doses.
Qualcomm
How it makes money
Qualcomm earns money in two ways. QCT (Qualcomm CDMA Technologies) designs Snapdragon systems-on-chip, modems, RF front-end and Wi-Fi/Bluetooth chips and sells them to handset, automotive, PC and IoT customers; manufacturing is outsourced to foundries such as TSMC and Samsung. QCT produced $38.367B of FY2025 revenue, including $27.793B from handsets, $6.617B from IoT and $3.957B from automotive.
Growth strategy
Qualcomm's growth plan is to reuse Snapdragon's low-power compute, connectivity and AI engines outside phones. Automotive is the clearest win so far, with the Snapdragon Digital Chassis growing from $2.9B in FY2024 to $3.957B in FY2025 and $1.6B in Q3 FY2026 alone. Snapdragon X chips target Windows Copilot+ laptops. Industrial IoT and robotics carry a design-win pipeline above $7B.
Competitive advantage
Qualcomm's edge comes from pairing leading cellular modem and RF engineering with one of the largest portfolios of standard-essential wireless patents. That combination lets it sell integrated Snapdragon platforms (CPU, GPU, NPU, modem and RF) while still collecting royalties on phones that use rival chips. Its custom Oryon CPU cores, from the 2021 Nuvia deal, now run in both flagship phone and Windows PC chips.
Questions about Pfizer vs Qualcomm
Which company has higher revenue — Pfizer Inc. or Qualcomm Inc.?
Pfizer Inc. reported $62.6B (FY2025), while Qualcomm Inc. reported $44.3B (FY2025). By last reported revenue, Pfizer Inc. is the larger business, with Qualcomm Inc. reporting a smaller revenue base.
What is the market cap of Pfizer Inc. vs Qualcomm Inc.?
Pfizer Inc.'s market capitalisation stands at $160.3B, while Qualcomm Inc.'s is $208.0B. Qualcomm Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Pfizer Inc..
Which is more financially efficient — Pfizer Inc. or Qualcomm Inc.?
Pfizer Inc. generates $834k / employee in revenue per employee, while Qualcomm Inc. generates $852k / employee. Qualcomm Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Pfizer Inc. and Qualcomm Inc. make money?
Pfizer Inc. and Qualcomm Inc. generate revenue in fundamentally different ways. Pfizer Inc.: Pfizer makes money by selling patented prescription medicines and vaccines to wholesalers, hospitals, governments and pharmacies, with the United States as its largest market. Qualcomm Inc.: Qualcomm earns money in two ways.
Which company is valued higher relative to revenue — Pfizer Inc. or Qualcomm Inc.?
On a price-to-sales (P/S) basis, Pfizer Inc. trades at 2.6x P/S and Qualcomm Inc. at 4.7x P/S. Qualcomm Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Pfizer Inc. bigger than Qualcomm Inc.?
By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to Qualcomm Inc. ($44.3B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Pfizer vs Qualcomm overview